.jpg)
Through our efforts aimed at social implementation of advanced medicine, such as support of life science research and development of gene therapy, we are working to create a society in which people can stay well and enjoy life.
Takara Bio Group offers a wide variety of products and services in the life sciences field, ranging from those for basic research to those with industrial applications. We are supporting the growth of research in the life sciences by providing universities and businesses around the world with a stable supply of these products.
As demand for PCR testing grows amidst the pandemic, we are working to build up the testing system by strengthening our production system and providing a stable supply of PCR-related products and internationally.
We have also actively expanded our genetic analysis technology to testing and diagnostics, and are helping people be well by expanding the scope of this technology.
We are supporting the life science community by sponsoring various life science and bio-related academic conferences and events including technology seminars targeting bio researchers. We are also working to promote social understanding of biotechnology by participating in seminars held at universities and organizations and hosting publicity workshops for university students.
We also commercialize promising academic technology seeds through open innovation.
We have also been working to improve access to medical care for rare diseases by leveraging the biotechnology we have cultivated over many years in clinical development of gene therapy for rare cancers and other rare diseases. We are aiming to bring socially impactful regenerative medicine products such as gene therapies to market through our CDMO business to address unmet medical needs.
Theme: Supporting life science research and its development around the world
|
Measures |
Targets for FY2026 |
Description |
|
Wide-ranging support for life science research and industrial development. |
Promote the development of global, multipolar manufacturing facilities (Japan, the U.S., Europe, and China) and support the development of life science research through stable product supply. |
Move forward with the transfer of manufacturing from China's core plants to Japan, the U.S., Europe, and India. |
|
Contributing to life science community. |
1) Disseminate information about biotechnology fundamentals and the latest technology by holding seminars and workshops. |
・Hold about 250 webinars a year for bio-researchers. |
|
・Hold corporate sponsored seminars at academic societies (several times a year). |
||
|
2) Commercialize promising academic discoveries through open innovation. |
As a commercialization of academic technology seeds, started clinical trials of JAK/STAT techniques (TBI-2001), etc. |
|
|
3) Promote social understanding of biotechnology. |
・Participation in seminars held by universities and scientific organizations (several times a year). |
|
|
・Holding public relations workshops for university students (once or twice a year). |
Theme: Application of gene analysis technologies to testing and diagnosis
|
Measures |
Targets for FY2026 |
Description |
|
Supply testing and diagnostic kits for viruses, etc. |
Expand the scope of application by developing "glocal" products customized to the characteristics and demands of each region in the world, in addition to virus testing products for infectious diseases that are prevalent worldwide. |
Expand the range of viruses and microbial species to be tested in line with the “glocal” needs. |
Theme: Initiatives to develop gene therapy
|
Measures |
Targets for FY2026 |
Description |
|
Promote the development of gene therapy-related technologies that meet unmet medical needs. |
1) Proceed with preparation for marketing authorization for TBI-1301 and make it a social implementation. |
Promote preparations for marketing authorization for TBI-1301. |
|
2) Promote CDMO business to support the development/ manufacturing of regenerative medicine/ gene and cell therapy. |
Provision of services for diverse modalities and mass production. |
|
|
3) Provide ancillary materials compatible with new modalities. |
Developing and launching enzymes for the production of mRNA. |
